Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > SIGA SIGA Technologies > Company Executives
SIGA SIGA Technologies
Post Mkt Price
NamePositionSalaryService DateEducationAgeGenderUpdated
Mr. Phillip Louis GomezChief Executive Officer and Director1.69M----55male04/27/2022
Dr. Dennis E. Hruby,PhDExecutive Vice President and Chief Scientific Officer1.30M----70male04/27/2022
Mr. Daniel LuckshireExecutive Vice President, Chief Financial Officer, Secretary and Principal Accounting Officer1.31M----51male04/27/2022
Mr. Jaymie A. DurnanIndependent Director199.70K----68male04/27/2022
Mr. Joseph W. Marshall, IIIIndependent Director215.48K----69male04/27/2022
Mr. Michael C. PlanskyLead Independent Director219.34K----72male04/27/2022
Ms. Julie M. KaneIndependent Director212.27K----63female04/27/2022
Mr. Julian NemirovskyIndependent Director197.81K----38male04/27/2022
Dr. Gary J. Nabel, M.D.,PhDIndependent Director303.23K----68male04/27/2022
Dr. Holly Phillips, M.D.Independent Director303.23K----51male04/27/2022
Company Overview More
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
CEO: Gomez III, M.D., Ph.D., Phillip Louis
Market: NASDAQ
Futu Hot List
SymbolLatest price%Chg


Back to the Top